Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Observational Study of Efficacy and Safety of Travogen Cream and Travocort Cream in the Treatment of Mycoses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00722189
Recruitment Status : Completed
First Posted : July 25, 2008
Last Update Posted : March 19, 2015
Information provided by (Responsible Party):

Brief Summary:
An assessment of the efficacy and safety of Travogen cream and Travocort cream in the treatment of local skin mycoses

Condition or disease
Skin Mycoses

Layout table for study information
Study Type : Observational
Actual Enrollment : 900 participants
Time Perspective: Prospective
Official Title: Observational Study of the Efficacy, Safety and Tolerance of Travogen Cream (Isoconazole) and Travocort Cream (Isoconazole, Diflurcortolone) in the Treatment of Patients With Local Skin Mycosis of Various Etiology and Localization
Study Start Date : July 2008
Actual Primary Completion Date : January 2009
Actual Study Completion Date : February 2009

Resource links provided by the National Library of Medicine

All patients treated

Primary Outcome Measures :
  1. Efficacy of Travogen / Travocort in the treatment of skin mycoses / Travogen Cream and Travocort Cream will be prescribed by a physician [ Time Frame: Baseline to end of study ]

Secondary Outcome Measures :
  1. Patient satisfaction [ Time Frame: Baseline to end of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with diagnosed skin mycoses

Inclusion Criteria:

  • Diagnosis of skin mycosis

Exclusion Criteria:

  • Allergies to study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00722189

Layout table for location information
Russian Federation
Kashkin Clinical Research Mycological Institute
St Petersburg, Russian Federation
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer

Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00722189    
Other Study ID Numbers: 2008/01850
First Posted: July 25, 2008    Key Record Dates
Last Update Posted: March 19, 2015
Last Verified: March 2015
Keywords provided by Bayer:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Infectious
Skin Diseases
Antifungal Agents
Anti-Infective Agents